Latest Morning Briefing Stories
The investment required to globalize has been daunting to the hospital industry. But facing anemic growth and other troubles, some hospitals are looking abroad. Meanwhile, Anthem is being taken to court over its new policies that restrict outpatient imaging and emergency department reimbursement.
The drug industry trade group focused its spending on issues such as generics, the “doughnut hole,” and trade.
Many physicians are being trained at hospitals that have been cited for deficiencies by the Centers for Medicare and Medicaid Services.
“We’re not suggesting that nobody is seeing higher costs,” said Murray Aitken, of the IQVIA Institute for Human Data Science, which released the numbers. “We’re just saying that when we roll everything up, the amount received by manufacturers rose by only 0.6 percent in 2017.”
The program had provided more than $100 million a year to 81 groups and institutions serving about 1.2 million teens, but the administration abruptly cut off grants last year, arguing that the programs were ineffective at curbing teenage pregnancy.
Drugmakers are expecting to take a financial hit from the copay accumulator programs that PBMs have begun marketing. And the Supreme Court may review a whistleblower case that could have implications across the pharmaceutical industry.
Lawmakers in the California Senate health committee are set to vote Wednesday on a measure that would crack down on third-party premium assistance for dialysis patients. The bill has the backing of insurers and powerful labor groups.
Sen. Jon Tester (D-Mont.) met with Dr. Ronny Jackson, President Donald Trump’s choice to lead the troubled Veterans Affairs Department, ahead of a confirmation hearing next week. Privatization has become a hot-button topic when it comes to veterans health care.
President Donald Trump’s remarks are expected to coincide with a formal request for information from HHS on various ideas to lower prescription drug costs.
The tactic of suing companies over potentially harmful products is a lucrative one, and those looking to get a chunk of that money have made a business out of luring women into sometimes unnecessary procedures to make them a more valuable plaintiff.
Generic drug developers need samples of brand-name drugs to show that a generic copy is equivalent to the original, but the drug companies are refusing to provide samples of their products. In other pharmaceutical news: an appeals court hands the industry a victory in price gouging case; a former Mallinckrodt employee claims she was fired for warning company about illegal sales practices; and a shortage of EpiPens outside the U.S.
An analysis finds that the new medications, which could carry a $8,500 price tag, are not cost effective. In other pharmaceutical news, a gene therapy trial for Duchenne muscular dystrophy has begun, and an online pharmacy is fined for importing counterfeit cancer drugs.
News outlets report on stories related to pharmaceutical pricing.
The measure, which is backed by influential unions and opposed by providers, faces an uphill battle in the state Legislature.
Overall, the Trump administration’s rules addressing the standards for insurers planning to participate in health law marketplaces give more control and further flexibility over to states.
G. Ford Gilbert’s IV insulin infusions for diabetes wounds have been called scams, but still his nationwide system of clinics that offer the procedures has been thriving.
In the fight against the national drug epidemic, there’s now a larger focus on medication-based treatments. So, where should advocates draw the line in terms of working with drugmakers when it comes to conflicts of interest? Meanwhile, a new report details the cost to employers of treating opioid addiction.
CMS Administrator Seema Verma says the payment bump reflects higher projections for how much Medicare spending will increase next year.
But advocates and drug companies say that would harm patients and be a radical departure from how Medicaid operates now. The decision could have a nationwide impact as states look at ways to bring down spiking drug costs. Meanwhile, a new study supports the industry’s argument that even as list prices rise, net prices are going down with discounts like rebates.
Each week, KHN compiles a selection of recently released health policy studies and briefs.